BMJ Open

Risk factors for 30-day in-hospital mortality for in-patient with stroke in sub-Saharan Africa: protocol for a systematic review and meta-analysis

Martin Ackah ,[1] Cynthia Osei Yeboah,[1] Louise Ameyaw[2]

To cite: Ackah M, Yeboah CO, Ameyaw L. Risk factors for 30-day in-hospital mortality for in-patient with stroke in sub-Saharan Africa: protocol for a systematic review and meta-analysis. *BMJ Open* 2021;**11**:e049927. doi:10.1136/bmjopen-2021-049927

► Prepublication history and additional online supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2021-049927).

Received 08 February 2021
Accepted 09 July 2021

[1]Department of Physiotherapy, Korle Bu Teaching Hospital, Accra, Greater Accra, Ghana
[2]School of public Health, University of Ghana College of Health Sciences, Accra, Greater Accra, Ghana

Correspondence to
Martin Ackah;
martinackah10@gmail.com

ABSTRACT

Introduction While individual studies have reported on in-hospital stroke mortality rates in sub-Saharan Africa (SSA), the estimates are highly variable and inconclusive, buttressing the need for precise and reliable estimations. To overcome these inconsistencies, a well-structured systematic review and meta-analytical models are necessary. However, to the best of our knowledge, there is no published systematic review and meta-analysis on risk factors for 30-day mortality for in-hospital patients with stroke in SSA.

Method and analysis We will include all retrospective and prospective facility-based observational studies reporting on the incidence and/or risk factors for in-hospital stroke mortality in SSA. Electronic databases such as PubMed, Google scholar and Africa Journal Online (AJOL) will be searched for potentially relevant studies on in-hospital stroke mortality and risk factors in SSA. The search will be limited to studies conducted from January 1990 to December 2020. Two independent authors will screen titles and abstract to find studies that meet the prespecified eligibility criteria for inclusion in the review. The incidence of 30-day in hospital stroke mortality will be pooled. Meta-regression will be used to assess the factors associated with in-hospital stroke mortality in SSA. If possible, subgroup analysis will be performed based on subregion, publication year and study design, and quality score to determine possible source of heterogeneity. If possible, a sensitivity analysis will be performed to determine the robustness of the estimates obtained from the meta-analysis.

Ethics and dissemination Ethical approval is not required as this is a secondary research and will use reported data in scientific literature. A full manuscript will be submitted to a reputable peer-review journal for publication.

PROSPERO registration number CRD42021227367.

Strengths and limitations of this study

- ► To the best of the authors' knowledge, this is the first systematic review and meta-analysis on risk factors for 30-day in-hospital stroke mortality rate in sub-Saharan Africa.
- ► Sensitivity analyses will be performed to determine the robustness of the estimates obtained from the meta-analysis.
- ► We would incorporate well-validated systematic review and meta-analysis technique that are completely consistent with existing international standards and recommendations.
- ► Due to regional and geographical differences, there can be variations across studies, therefore, we plan to conduct robust sub-group analyses to detect any subgroup effects.
- ► Papers/articles that have only been published in English would be considered, which could introduce publication bias.

INTRODUCTION

Stroke is a major cause of death and injury, and poststroke treatment costs are a significant economic burden worldwide.[1 2] High-income countries have seen rapid and significant reduction in stroke incidence, and long-term survival as a result of expanded use of preventive therapies and significant decreases in premorbid risk factors.[3–5] Nonetheless, most sub-Saharan Africa countries (SSA) are unable to say same.[6]

The incidence of stroke is rising in low-income and middle-income countries (LMICs) in SSA countries, and research has shown that between 2002 and 2020, stroke mortality in SSA was tripled.[7 8] For instance, community-based SSA studies indicate that 5%–10% of all deaths are caused by stroke, partially due to poor health system and rising rates of hypertension.[9 10] In addition, LMICs account for 85% of all stroke deaths, as well as 87% of total losses due to stroke measured in disability-adjusted life-years which total 72 million per year worldwide[1 11]

In SSA, epidemiological studies have shown that in-hospital stroke mortality rates varied from 18% in Ethiopia to 43% in Ghana.[8 12] SSA countries have insufficient resources for acute medical and rehabilitation care for stroke, therefore, comprehensive and

pragmatic preventive efforts directed at risk factors are of utmost importance to curtail the burden.[13] In the same vein, early intervention on in-patient with stroke identified with a high risk of mortality may increase the survival rate.[14] It is, therefore, imperative to identify risk factors for 30-day in-hospital mortality for in-patients with stroke in SSA. The proportion of patients who die within 30 days from the time of admission to the time of death among all patients hospitalised with stroke is referred to as 30-day in-hospital stroke mortality.

While individual studies have reported on in-hospital stroke mortality rates in SSA, the estimates are highly variable and inconclusive, buttressing the need for precise and reliable estimations. To overcome these inconsistencies, a well-structured systematic review and meta-analytical models are necessary. However, to the best of our knowledge, there is no published systematic review and meta-analysis on risk factors for 30-day mortality for in-hospital patients with stroke in SSA.

With this in mind, the study seeks to systematically review empirical evidence on risk factors for 30-day mortality for in-hospital patients with stroke in SSA. It is important for healthcare providers to learn about the risk factors associated with in-hospital stroke 30-day mortality in order to prepare for future patient care as well as to optimise hospital staffing and necessary skills in SSA.

Review questions

- What is the incidence for 30-day mortality rates for in-patients with stroke in SSA?
- What are the risk factors for 30-day mortality rates for in-patients with stroke in SSA?

Objectives

- Primary objective: To determine the incidence for 30-day mortality rates for in-patients with stroke in SSA.
- Secondary objective: To assess the risk factors for 30-day mortality for in-patients with stroke in SSA.

METHODS

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Ethics and dissemination

Ethical approval is not required as this is a secondary research and will use reported data in scientific literature. A full manuscript will be submitted to a reputable peer-review journal for publication.

Protocol registration and best practices

This systematic review and meta-analysis will follow strict adherence to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) [15] (online supplemental file 2).

Eligibility

Types of studies

All retrospective and prospective facility-based observational studies reporting on incidence and/or risk factors for in-hospital stroke mortality and case fatality in SSA countries. Also, if any of the countries in SSA have a public reporting of in-hospital 30-day mortality from eventual published quality indicators, such outcome will be included to help contribute to the identification and understanding of risk factors. Animal studies, reviews, commentaries, conference papers and letter to the editor will be excluded.

Types of participants

Studies from SSA countries involving in-hospital patients with stroke. The review will consider all age groups.

Types of outcome measures

The primary outcome is the in-hospital stroke 30-day mortality in SSA and secondary outcome is the risk factors for in-hospital mortality in SSA. However, if any study reports on out-of-hospital mortality, it will be extracted and reported separately.

Data source and search strategies

Primary electronic search in English on the incidence and risk factors for in-hospital stroke case-fatality rate in SSA will be conducted in MEDLINE via PubMed, Google Scholar and AJOL. The search will be limited to studies conducted from January 1990 to December 2020. Table 1 displays the main search term and approaches (online supplemental file 1). The abstracts of all eligible papers will then be reviewed and full articles will be accessed through PubMed, Google Scholar, and AJOL. Reference lists of papers that fulfil the eligibility requirements of the study will be reviewed to identify additional studies not included in our electronic search. To ensure that potential studies that will be missed by electronic searching are included, experts will be consulted.

Screening and selecting studies

Two authors will screen titles and abstract independently to find studies that meet the pre-specified eligibility criteria for inclusion in the review. Full texts of all potentially relevant studies will be accessed and assessed in detail in a similar manner. A third reviewer will be available to resolve any discrepancies between the two independent assessors. A screening guide will be used to ensure that independent reviewers apply the selection criteria reliably. Authors whose full-text documents are not available via a variety of internet-based sources will be contacted directly through the corresponding authors to provide them to help make the final decision about inclusion. If vital information needed to make the inclusion decision is not obtained, the article will be excluded. Mendeley reference manager will be used to deduplicate studies.

Table 1 Search string for PubMed, Google scholar and AJOL

Search #	Search term
1)	In-hospital OR in-patient
2)	Stroke OR cerebrovascular accident OR CVA OR cerebral infarction OR Ischemic stroke OR Lacuna stroke OR cerebral hemorrhage OR haemorrhagic stroke
3)	1 AND 2
4)	Mortality OR 30-day mortality OR death OR case-fatality
5)	3 AND 4
6)	risk factors OR associated factors
7)	5 OR 6
8)	sub-Saharan Africa
9)	Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR Cameroon OR Cape Verde OR Central African Republic OR Chad OR Comoros OR Congo OR Cote d'Ivoire OR Djibouti OR Equatorial Guinea OR Ethiopia OR Gabon OR The Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Kenya OR Lesotho OR Liberia OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR Sao Tome and Principe OR Senegal OR Seychelles OR Sierra Leone OR Somalia OR South Africa OR Sudan OR Swaziland OR Tanzania OR Togo OR Uganda OR Zaire OR Zambia OR Zimbabwe
10)	8 OR 9
11)	Limit to January, 1990-December,2020
12)	Limit to Humans
13)	10 AND 11 AND 12

Data extraction and management

Two independent assessors will extract the data from the eligible published articles using a pretested and standardised excel spreadsheet. Data such as the last name of the first author's name, year of publication, study country, study design, sample size, mortality rate, risk factors for in-hospital stroke case-fatality, severity measure, type of stroke as well as the demographic information (ie, sex, age, etc) will be extracted. Missing data will be addressed by contacting the corresponding author for insufficient or unclear data. If possible, corresponding authors will be asked to provide us with the raw data to extract the missing data.

Outcome and operationalisation

A 30-day in-hospital stroke mortality is operationally defined as the proportion or standardised hospital mortality based on the number of patients who die within 30 days from the time of admission to the time of death among all patients hospitalised with stroke. In this study, a risk factor is defined as a set of variables that are linked to or cause 30-day death in hospitalised stroke patients in SSA. For example, patient-related factors that may increase mortality in stroke include poor control of major risk factors to stroke such as hypertension, obesity, smoking, heart disease and diabetes. Hospital-related factors such as availability of a stroke unit, availability of an intensive care unit and the capacities of the emergency unit. Treatment delays (ie, waiting times, time to get to hospital from onset of symptoms). The severity of stroke and length of stay may also influence 30-day mortality, etc.

Risk of bias and quality assessment

The Newcastle-Ottawa Quality Assessment tool adapted for cross-sectional studies will be used to assess the quality of the retrieved studies[16]. The purpose of the assessment will be to determine the internal and external validity of the studies and to minimise risk of bias.

Data synthesis

Extracted data will be exported into Stata (V.16; Stata) from Microsoft excel 2013 for all analyses. The PRISMA flow chart (figure 1) will be used to summarised the selection process. When considerable homogeneity exists among the studies, the incidence of 30-day in-hospital stroke mortality in SSA will be pooled. This will be visually represented using the forest plot. The presence of heterogeneity among studies will be quantified by estimating variance using both Cochrane's Q statistics and the I^2 statistics.[17] The I^2 takes values between 0% and 100%, and a value of 0% indicates absence of heterogeneity. I^2 will be interpreted based on Higgins and Thompson classification, percentages of 25%, 50% and 75% will be considered as low, moderate and high heterogeneity, respectively.[17]

Meta-regression will be used to assess the factors associated with in-hospital stroke 30-day mortality in SSA. If possible, subgroup analysis will be performed based on subregion (West Africa vs East Africa vs Southern Africa), publication year and study design (prospective vs retrospective), and quality score (low risk vs moderate risk vs high risk of bias) to determine possible source of heterogeneity.

If possible, a sensitivity analysis will be performed to determine the robustness of the estimates obtained from the meta-analysis. We will do sensitivity analysis on the quality of the studies included in the systematic review and meta-analysis, that is, studies with low quality score will initially be excluded to check their direction and impact on the overall (pooled) estimate and finally leave one out sensitivity analysis will be performed. Publication bias will be checked by the funnel plot and Egger's test. Furthermore, trim and fill analysis will be used to adjust for publication bias using Duval and Tweedie's method[18] in case publication bias exist.

In event where meta-analysis is not possible due to considerable heterogeneity and low-quality studies, narrative systematic review will be presented.



Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols flow chart for study selection.

Grading the quality of evidence

The quality of evidence for all studies will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group methodology. The following domains will be assessed: risk of bias, consistency, directness, precision, publication bias and additional points. The assessments will be classified into four levels: high, moderate, low or very low.[19] Two independent reviewers will assess the GRADE and disagreement will be resolved through discussion.

Expected key results and discussion

Globally, stroke is the third leading cause of death.[20] The bulk of these deaths from strokes are found in LMICs. In these nations, deaths account for up to 87% of all stroke fatalities.[21] This elevated death toll is much greater in SSA.[21] To the best of the authors' knowledge, there is no comprehensive systematic review and meta-analysis on in-hospital stroke case fatality exist in SSA. Hence, the primary aim of this review is to determine the incidence of in-hospital stroke 30-day mortality in SSA. Secondary objective is to assess the risk factors for in-hospital stroke mortality in SSA.

Acknowledgements Sincere thanks to Nana Abena Nyamedo Yeboah for critical reading of the manuscript and comments.

Contributors MA conceived the study, drafted the manuscript, critically revised the manuscript for methodological and intellectual content. COY drafted the manuscript, critically revised the manuscript for methodological and intellectual content. LA critically revised the manuscript for methodological and intellectual content. All authors approved the final manuscript. MA is the guarantor of the review.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

ORCID iD
Martin Ackah http://orcid.org/0000-0002-5045-1104

REFERENCES

1 GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the global burden of disease study 2016. *Lancet Neurol* 2019;18:439–58.
2 Rajsic S, Gothe H, Borba HH, *et al*. Economic burden of stroke: a systematic review on post-stroke care. *Eur J Health Econ* 2019;20:107–34.
3 Rothwell PM, Coull AJ, Giles MF, *et al*. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford vascular study). *Lancet* 2004;363:1925–33.
4 Peltonen M, Stegmayr B, Asplund K. Time trends in long-term survival after stroke. *Stroke* 1998;29:1358–65.
5 Eriksson M, Carlberg B, Eliasson M. The disparity in long-term survival after a first stroke in patients with and without diabetes persists: the Northern Sweden MONICA study. *Cerebrovasc Dis* 2012;34:153–60.
6 Sanya E, Wahab KW, Bello AH, *et al*. In-hospital stroke mortality and its predictors within one month of ictus: result from a tertiary hospital in Ilorin, middle belt Nigeria. *Sub-Saharan Afr J Med* 2015;2:165–9.
7 World Health Organization. *Towards a who long-term strategy for prevention and control of leading chronic diseases*, 2004.
8 Kaduka L, Muniu E, Oduor C, *et al*. Stroke mortality in Kenya's public tertiary hospitals: a prospective Facility-Based study. *Cerebrovasc Dis Extra* 2018;8:70–9.
9 Agyemang C, Attah-Adjepong G, Owusu-Dabo E, *et al*. Stroke in Ashanti region of Ghana. *Ghana Med J* 2012;46:12–17.
10 Sanuade OA, Dodoo FN-A, Koram K, *et al*. Prevalence and correlates of stroke among older adults in Ghana: evidence from the study on global ageing and adult health (SAGE). *PLoS One* 2019;14:e0212623–17.
11 Dabilgou AA, Dravé A, Kyelem JMA, Marie J, *et al*. Frequency and mortality risk factors of acute ischemic stroke in emergency department in Burkina Faso. *Stroke Res Treat* 2020;2020:9745206.
12 Alene M, Assemie MA, Yismaw L, *et al*. Magnitude of risk factors and in-hospital mortality of stroke in Ethiopia: a systematic review and meta-analysis. *BMC Neurol* 2020;20:1–10.
13 Owolabi MO, Sarfo F, Akinyemi R, *et al*. Dominant modifiable risk factors for stroke in Ghana and Nigeria (siren): a case-control study. *Lancet Glob Health* 2018;6:e436–46.
14 Zhang R, Wang Y, Fang J, *et al*. Worldwide 1-month case fatality of ischaemic stroke and the temporal trend. *Stroke Vasc Neurol* 2020;5:353–60.
15 Shamseer L, Moher D, Clarke M, *et al*. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647–25.
16 Luchini C, Stubbs B, Solmi M, *et al*. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa scale. World J Metaanal 2017;5:80.
17 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–58.
18 Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56:455–63.
19 Balshem H, Helfand M, Schünemann HJ, *et al*. Grade guidelines: 3. rating the quality of evidence. *J Clin Epidemiol* 2011;64:401–6.
20 Feigin VL, Lawes CMM, Bennett DA, *et al*. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. *Lancet Neurol* 2009;8:355–69.
21 Ekeh B, Ogunniyi A, Isamade E, *et al*. Stroke mortality and its predictors in a Nigerian teaching hospital. *Afr Health Sci* 2015;15:74–18.

***Supplementary file 1**: Search string for PubMed, Google scholar and AJOL*

Search #	Search term
1)	In-hospital OR in-patient
2)	Stroke OR cerebrovascular accident OR CVA OR cerebral infarction OR Ischemic stroke OR Lacuna stroke OR cerebral hemorrhage OR haemorrhagic stroke
3)	1 AND 2
4)	mortality OR 30-day mortality OR death OR case-fatality
5)	3 AND 4
6)	risk factors OR associated factors
7)	5 OR 6
8)	sub-Saharan Africa
9)	Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR Cameroon OR Cape Verde OR Central African Republic OR Chad OR Comoros OR Congo OR Cote d'Ivoire OR Djibouti OR Equatorial Guinea OR Ethiopia OR Gabon OR The Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Kenya OR Lesotho OR Liberia OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR Sao Tome and Principe OR Senegal OR Seychelles OR Sierra Leone OR Somalia OR South Africa OR Sudan OR Swaziland OR Tanzania OR Togo OR Uganda OR Zaire OR Zambia OR Zimbabwe
10)	8 OR 9
11)	Limit to January, 1990-December,2020
12)	Limit to Humans
13)	10 AND 11 AND 12

Checklist file 1: PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol

Section and topic	Item No	Checklist item	Page
ADMINISTRATIVE INFORMATION			
Title			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	NA
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	3 & 6
Authors: contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Authors' contribution	3b	Describe contributions of protocol authors and identify the guarantor of the review	12
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	NA
Support			
Sources	5a	Indicate sources of financial or other support for the review	12
Sponsor	5b	Provide name for the review funder and/or sponsor	NA
Role of funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	NA
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	4-5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6-7
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources with planned dates of coverage	7

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such 6 that it could be repeated	7
Study record			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	9
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	9
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any preplanned data assumptions and simplifications	-
Outcome and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	9
Risk of bias in the individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	9
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	10
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2, Kendall's τ)	10
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	10
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	11
Meta biases	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	10
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	11

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. BMJ [Internet]. 2015;349(January):1–25. Available from: http://dx.doi.org/doi:10.1136/bmj.g7647